Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02119468 · ClinicalTrials.gov registry record · Phase 1

Ixazomib Plus Pomalidomide and Dexamethasone in Treating Patients With Relapsed or Relapsed/Refractory Multiple Myeloma

A Phase 1 study of Refractory Plasma Cell Myeloma and Recurrent Plasma Cell Myeloma, sponsored by City of Hope Medical Center.

Completed
Registry status
Phase 1
Development phase
32
Enrollment target
5
Study locations

NCT02119468 is a Phase 1 study of Refractory Plasma Cell Myeloma and Recurrent Plasma Cell Myeloma that has completed, run by City of Hope Medical Center. The registered enrollment target is 32 participants, below the 46-participant average among 25 other Refractory Plasma Cell Myeloma trials with a reported enrollment target (30% lower). The trial reports 5 study locations across 5 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02119468, a Phase 1 study of Refractory Plasma Cell Myeloma and Recurrent Plasma Cell Myeloma, has completed, sponsored by City of Hope Medical Center.

COMPLETED
Registry status
Phase 1
Development phase
32 participants
Enrollment target
5
Study locations

Study Summary

This phase I/II trial studies the side effects and best dose of ixazomib and to see how well it works when given together with pomalidomide and dexamethasone in treating patients with relapsed or relapsed/refractory multiple myeloma. Ixazomib may stop the growth of cancer by interfering with proteasomes (the protein breakdown mechanism in the cells). Pomalidomide and dexamethasone can modify and regulate the immune system and may stop cancer cells from growing. Giving ixazomib with pomalidomide and dexamethasone may be an effective treatment for relapsed or relapsed/refractory multiple myeloma.

Conditions Studied

Refractory Plasma Cell Myeloma Recurrent Plasma Cell Myeloma

Interventions

  • DRUG dexamethasone
  • DRUG pomalidomide
  • DRUG ixazomib citrate

Study Locations (5)

Arizona

  • Mayo Clinic - Scottsdale

California

  • City of Hope Medical Center - Duarte

Georgia

  • Emory University/Winship Cancer Institute - Atlanta

Minnesota

  • Mayo Clinic - Rochester

Tennessee

  • Sarah Cannon Research Institute (SCRI) - Nashville

Trial Details

FieldValue
Enrollment Target 32 participants
Start Date 2014-06-30
Est. Completion 2022-12-01
Phase Phase 1

Sponsor

City of Hope Medical Center

582 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT02119468

The ClinicalTrials.gov registry entry for NCT02119468 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 46-participant average among 25 other Refractory Plasma Cell Myeloma trials with a reported enrollment target (30% lower). The listed sponsor is City of Hope Medical Center, which has 582 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Refractory Plasma Cell Myeloma appearing as the primary indexed condition, and to 3 interventions - of which dexamethasone is the first listed.

NCT02119468 reports 5 study locations spanning 5 distinct geographic areas - top geographies include Arizona, California, Georgia.

Frequently Asked Questions

What is clinical trial NCT02119468 about?

NCT02119468 is a clinical study titled "Ixazomib Plus Pomalidomide and Dexamethasone in Treating Patients With Relapsed or Relapsed/Refractory Multiple Myeloma". This phase I/II trial studies the side effects and best dose of ixazomib and to see how well it works when given together with pomalidomide and dexamethasone in treating patients with relapsed or relapsed/refractory multiple myeloma. Ixazomib may stop the growth of cancer by interfering with proteas...

What is the current status of trial NCT02119468?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 32 participants. The study started on 2014-06-30. Estimated completion is 2022-12-01.

What conditions does trial NCT02119468 study?

This clinical trial studies the following conditions: Refractory Plasma Cell Myeloma, Recurrent Plasma Cell Myeloma.

What interventions are being tested in trial NCT02119468?

The interventions under investigation include: dexamethasone (DRUG), pomalidomide (DRUG), ixazomib citrate (DRUG).

Who is sponsoring clinical trial NCT02119468?

This trial is sponsored by City of Hope Medical Center, which has 582 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02119468 being conducted?

This trial has 5 study locations across Arizona, California, Georgia, Minnesota, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Refractory Plasma Cell Myeloma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Refractory Plasma Cell Myeloma

All registered trials for this condition

Recurrent Plasma Cell Myeloma

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.